3TC (Lamivudine; GR109714X) Open-Label Program

Completed · Not applicable

Conditions studied: HIV Infections

In brief

To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies. To collect data pertaining to the safety of 3TC at two dose levels. To evaluate the effect of 3TC on markers of hepatitis B in co-infected patients at five to ten selected sites.

Key facts

Study ID

NCT00002108

Run by

Glaxo Wellcome

Last updated by the study team

2005-06-24

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Kern - McNeill International — Morristown, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.